CAS: 170793-00-7; Magnesium,1-Chloro-2-Fluorobenzene-4-Ide,Bromide

该化合物是一种Grignard试剂,是一种有机合成中常见的有机磁性化合物,用于形成碳结层,这种化合物的特点是用氯和氟原子替代的苯环,有助于其反应和在各种化学反应中的潜在应用;镁原子的存在表明,它可以作为核素发挥作用,允许它与电极发生反应,形成新的碳结层;溴离子是一种反作用,稳定溶液中的红色试剂.通常,灰色试剂对湿气和空气敏感,需要无水环境加以储存和使用.它们经常用于酒精,氯酮和其他复杂的有机分子的合成.氯和氟亚化合物的独特组合可以影响化合物的电子特性和反应,使其成为合成有机化学中有价值的中间体.适当的处理和安全防范措施对于红色试剂的再活性至关重要.

英文名称Magnesium,1-Chloro-2-Fluorobenzene-4-Ide,Bromide
中文名称4-氯-3-氟苯基溴化镁
IUPAC名称magnesium;1-chloro-2-fluorobenzene-4-ide;bromide
其它别名3-Fluoro-4-chlorophenylmagnesiumbromide; 4-Chloro-3-fluorophenylmagnesium bromide
CAS编号170793-00-7
MFCD编号:MFCD02260213
EINECS号:694-927-3
分子式:C6H3BrClFMg
分子量:233.75
产品CID: 874034
产品分类有机原料 → 有机金属类化合物 → 有机镁

相似结构搜索
InChIKey: GBIXREWYSCYTGZ-UHFFFAOYSA-M
InChI=1S/C6H3ClF.BrH.Mg/c7-5-3-1-2-4-6(5)8;;/h1,3-4H;1H;/q;;+1/p-1…
计算化学: 氢键受体数3.0氢键供体数0.0可旋转键数0.0

MSDS等安全信息

GHS象形图
GHS符号GHS05;
注释: Corrosion
危险类别皮肤腐蚀类别1B
严重眼损伤类别1
警示词Danger(危险)
危险描述H314 |造成严重皮肤灼伤和眼损伤.
H318 |造成严重眼损伤.
防范说明P210-P280-P301+P312+P330-P305+P351+P338-P370+P378-P403+P235-P260h-P303+P361+P353-P405-P501a
危险等级3
UN编号UN 2924 3/PG 2
危险品标志F,C,Xn
风险等级Flammable
安全声明16-26-33-36/37/39-45-36/37
危险类别码11-14-19-22-34-40-36/37
WGK Germany1

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号60811-18-9 4-溴-1-氯-2-氟苯 | CAS号348-60-7 4-氯-3-氟苯酚 | CAS号787585-34-6 2-氟-4-(2-甲基烯丙基)氯苯

合成工艺路线路线简述

海关参考信息

2903919090-氯苯
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-9861636-B2
优先权日:2014-04-29
标题 :Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
发明人：HE WEI
权利人:HE WEI; ZHEJIANG DTRM BIOPHARMA CO LTD
摘要:Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.